Monoamine oxidase inhibitors are type of drugs that inhibit the action of single or more monoamine oxidase enzymes such as monoamine oxidase A and monoamine oxidase B. These were the first type of antidepressant drugs manufactured. Since last many years’ monoamine oxidase inhibitors (MAOIs) are used medicines and prescribed for treatment of depression, anxiety, dysthymia, Parkinson’s disease, and other disorders. Just like most other antidepressants, MAOIs work on mechanism of overall brain chemistry which is responsible for treating depression. Monoamine oxidase enzyme has the ability to remove neurotransmitters serotonin, dopamine, and norepinephrine from the brain. Monoamine oxidase inhibitors inhibit this condition, which makes altercations in circuits affected by depression.
Monoamine oxidase inhibitors are effective; however, in the past few years these have been substituted by other antidepressants which are safer and have less side effects compared. Monoamine oxidase inhibitors generally require certain diet restrictions as these can severely affect blood pressure of a patient when taken with other prescribed medications or other food such as cheese and cured meats. These also have a high risk of drug interactions. Monoamine oxidase inhibitors (MAOIs) use also have huge risk of disturbing other neurotransmitters in the brain and digestive system, triggering side effects. Additionally, these could cause a withdrawal syndrome on discontinuation of medication.
Patients suffering from depression frequently complain about a feeling of nervousness and sadness, and continue to lose interest in routine work, as the disorder affects the way a person thinks, feels, and reacts causing a number of emotional and physical issues.
Depression and anxiety are the most common mental disorders among the global population. Increase in the number of patients suffering from depression is projected to drive the global monoamine oxidase inhibitors market. Youth (below 25 years of age) and women across the globe are increasingly being affected by anxiety and depression. Several government and concerned regulatory bodies have initiated different programs to increase awareness among people suffering from mental health and depression. This is anticipated to propel the global monoamine oxidase inhibitors market. However, side effects associated with MAOIs are expected to restrain the global market.
The global monoamine oxidase inhibitors (MAOIs) market can be segmented based on indication and end-user. In terms of indication, the global market can be classified into depression, Parkinson’s disease, and others. Based on end-user, the global monoamine oxidase inhibitors market can be categorized into hospitals, ambulatory surgical centers, academic & research institutes, and others.
Geographically, the global monoamine oxidase inhibitors (MAOIs) market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is the dominant market for monoamine oxidase inhibitors due to the presence of a large patient population suffering from depression and anxiety disorders. The market in the U.S. is saturated, as numerous antidepressant drugs are widely available on prescription for the same indication. Hence, the growth of the market in the country will depend on launch of new innovative products for various types of indications. Additionally, patent expiry, introduction of new generic products, and maturation of the market are the factors likely to hamper the growth of the global monoamine oxidase inhibitors (MAOIs) market. Europe and Asia Pacific are the other major markets for monoamine oxidase inhibitors. The market in Asia Pacific is projected to grow at a rapid pace in the next few years due to rise in number of people suffering from depression and rapid economic growth in countries such as India, Japan, China, and Australia.
Key players in the global monoamine oxidase inhibitors (MAOIs) market are Novartis, Pfizer, Inc., Validus Pharmaceuticals LLC, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., and Concordia Pharms, Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.